Literature DB >> 27268088

Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.

Sarah D Cramer1, Peter D Aplan2, Scott K Durum3.   

Abstract

Increased understanding of pediatric acute lymphoblastic leukemia (ALL) pathobiology has led to dramatic improvements in patient survival. However, there is still a need to develop targeted therapies to enable reduced chemotherapy intensity and to treat relapsed patients. The interleukin-7 receptor α (IL-7Rα) signaling pathways are prime therapeutic targets because these pathways harbor genetic aberrations in both T-cell ALL and B-cell precursor ALL. Therapeutic targeting of the IL-7Rα signaling pathways may lead to improved outcomes in a subset of patients.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27268088      PMCID： PMC4965903          DOI： 10.1182/blood-2016-03-679209

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  93 in total

1.  JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study.

Authors:  Vahid Asnafi; Sandrine Le Noir; Ludovic Lhermitte; Claude Gardin; Faézeh Legrand; Xavier Vallantin; Jean-Valère Malfuson; Norbert Ifrah; Hervé Dombret; Elizabeth Macintyre
Journal:  Br J Haematol       Date:  2009-09-18       Impact factor: 6.998

2.  Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.

Authors:  Priscila P Zenatti; Daniel Ribeiro; Wenqing Li; Linda Zuurbier; Milene C Silva; Maddalena Paganin; Julia Tritapoe; Julie A Hixon; André B Silveira; Bruno A Cardoso; Leonor M Sarmento; Nádia Correia; Maria L Toribio; Jörg Kobarg; Martin Horstmann; Rob Pieters; Silvia R Brandalise; Adolfo A Ferrando; Jules P Meijerink; Scott K Durum; J Andrés Yunes; João T Barata
Journal:  Nat Genet       Date:  2011-09-04       Impact factor: 38.330

3.  Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.

Authors:  Richard C Harvey; Charles G Mullighan; I-Ming Chen; Walker Wharton; Fady M Mikhail; Andrew J Carroll; Huining Kang; Wei Liu; Kevin K Dobbin; Malcolm A Smith; William L Carroll; Meenakshi Devidas; W Paul Bowman; Bruce M Camitta; Gregory H Reaman; Stephen P Hunger; James R Downing; Cheryl L Willman
Journal:  Blood       Date:  2010-02-04       Impact factor: 22.113

4.  Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.

Authors:  Charles G Mullighan; J Racquel Collins-Underwood; Letha A A Phillips; Michael G Loudin; Wei Liu; Jinghui Zhang; Jing Ma; Elaine Coustan-Smith; Richard C Harvey; Cheryl L Willman; Fady M Mikhail; Julia Meyer; Andrew J Carroll; Richard T Williams; Jinjun Cheng; Nyla A Heerema; Giuseppe Basso; Andrea Pession; Ching-Hon Pui; Susana C Raimondi; Stephen P Hunger; James R Downing; William L Carroll; Karen R Rabin
Journal:  Nat Genet       Date:  2009-10-18       Impact factor: 38.330

5.  TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.

Authors:  Qifang Zhang; Dewan Md Sakib Hossain; Sergey Nechaev; Anna Kozlowska; Wang Zhang; Yong Liu; Claudia M Kowolik; Piotr Swiderski; John J Rossi; Stephen Forman; Sumanta Pal; Ravi Bhatia; Andrew Raubitschek; Hua Yu; Marcin Kortylewski
Journal:  Blood       Date:  2013-01-03       Impact factor: 22.113

6.  IL-7 activates the phosphatidylinositol 3-kinase/AKT pathway in normal human thymocytes but not normal human B cell precursors.

Authors:  Sonja E Johnson; Nisha Shah; Anna A Bajer; Tucker W LeBien
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

7.  Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.

Authors:  Yongchao Wang; Warren Fiskus; Daniel G Chong; Kathleen M Buckley; Kavita Natarajan; Rekha Rao; Atul Joshi; Ramesh Balusu; Sanjay Koul; Jianguang Chen; Andrew Savoie; Celalettin Ustun; Anand P Jillella; Peter Atadja; Ross L Levine; Kapil N Bhalla
Journal:  Blood       Date:  2009-10-14       Impact factor: 22.113

8.  Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.

Authors:  Eun Goo Jeong; Min Sung Kim; Hyo Kyung Nam; Chang Ki Min; Seok Lee; Yeun Jun Chung; Nam Jin Yoo; Sug Hyung Lee
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

9.  Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.

Authors:  Shannon L Maude; Sarah K Tasian; Tiffaney Vincent; Junior W Hall; Cecilia Sheen; Kathryn G Roberts; Alix E Seif; David M Barrett; I-Ming Chen; J Racquel Collins; Charles G Mullighan; Stephen P Hunger; Richard C Harvey; Cheryl L Willman; Jordan S Fridman; Mignon L Loh; Stephan A Grupp; David T Teachey
Journal:  Blood       Date:  2012-09-06       Impact factor: 22.113

10.  Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.

Authors:  D Koyama; J Kikuchi; N Hiraoka; T Wada; H Kurosawa; S Chiba; Y Furukawa
Journal:  Leukemia       Date:  2013-12-04       Impact factor: 11.528
View more
  19 in total

1.  IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.

Authors:  Sara González-García; Marta Mosquera; Patricia Fuentes; Tiziana Palumbo; Adela Escudero; Antonio Pérez-Martínez; Manuel Ramírez; Anne E Corcoran; Maria L Toribio
Journal:  Blood       Date:  2019-12-12       Impact factor: 22.113

Review 2.  The promise of Janus kinase inhibitors in the treatment of hematological malignancies.

Authors:  Emilee Senkevitch; Scott Durum
Journal:  Cytokine       Date:  2016-10-27       Impact factor: 3.861

3.  Mutant IL-7Rα and mutant NRas are sufficient to induce murine T cell acute lymphoblastic leukemia.

Authors:  Sarah D Cramer; Julie A Hixon; Caroline Andrews; Ross J Porter; Gisele O L Rodrigues; Xiaolin Wu; Tim Back; Kelli Czarra; Helen Michael; Maggie Cam; Jack Chen; Dominic Esposito; Emilee Senkevitch; Vijay Negi; Peter D Aplan; Wenqing Li; Scott K Durum
Journal:  Leukemia       Date:  2018-02-15       Impact factor: 11.528

4.  Conservation of Intracellular Pathogenic Strategy among Distantly Related Cryptococcal Species.

Authors:  Joudeh B Freij; Man Shun Fu; Carlos M De Leon Rodriguez; Amanda Dziedzic; Anne E Jedlicka; Quigly Dragotakes; Diego C P Rossi; Eric H Jung; Carolina Coelho; Arturo Casadevall
Journal:  Infect Immun       Date:  2018-06-21       Impact factor: 3.441

5.  New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models.

Authors:  Julie A Hixon; Caroline Andrews; Lila Kashi; Casey L Kohnhorst; Emilee Senkevitch; Kelli Czarra; Joao T Barata; Wenqing Li; Joel P Schneider; Scott T R Walsh; Scott K Durum
Journal:  Leukemia       Date:  2019-08-22       Impact factor: 11.528

Review 6.  The genetics and molecular biology of T-ALL.

Authors:  Tiziana Girardi; Carmen Vicente; Jan Cools; Kim De Keersmaecker
Journal:  Blood       Date:  2017-01-23       Impact factor: 22.113

7.  Dual effect of IL-7/IL-7R signalling on the osteoimmunological system: a potential therapeutic target for rheumatoid arthritis.

Authors:  Haiyan Xu; Li Cai; Zijian Li; Lili Zhang; Guojue Wang; Rongli Xie; Yongshuai Jiang; Yuanyang Yuan; Hong Nie
Journal:  Immunology       Date:  2021-06-02       Impact factor: 7.215

8.  IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.

Authors:  Yunlei Li; Jessica G C A M Buijs-Gladdines; Kirsten Canté-Barrett; Andrew P Stubbs; Eric M Vroegindeweij; Willem K Smits; Ronald van Marion; Winand N M Dinjens; Martin Horstmann; Roland P Kuiper; Rogier C Buijsman; Guido J R Zaman; Peter J van der Spek; Rob Pieters; Jules P P Meijerink
Journal:  PLoS Med       Date:  2016-12-20       Impact factor: 11.069

9.  Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations.

Authors:  Emilee Senkevitch; Wenqing Li; Julie A Hixon; Caroline Andrews; Sarah D Cramer; Gary T Pauly; Timothy Back; Kelli Czarra; Scott K Durum
Journal:  Oncotarget       Date:  2018-04-27

10.  Cytotoxic Activity of Extracts from Plants of Central Argentina on Sensitive and Multidrug-Resistant Leukemia Cells: Isolation of an Active Principle from Gaillardia megapotamica.

Authors:  María Laura González; Mariana Belén Joray; Jerónimo Laiolo; María Inés Crespo; Sara María Palacios; Gustavo Miguel Ruiz; María Cecilia Carpinella
Journal:  Evid Based Complement Alternat Med       Date:  2018-05-10       Impact factor: 2.629
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.